Reported Sunday, Bristol Myers Squibb's Checkmate-067 Trial 10-Year Follow-Up Showed Continued Durable Long-Term Survival Benefit With Opdivo + Yervoy In Advanced Melanoma
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb's Checkmate-067 trial shows a 10-year follow-up with Opdivo + Yervoy in advanced melanoma, indicating a significant long-term survival benefit. Over 40% of patients were alive after ten years, compared to a 25% survival rate a decade ago.
September 16, 2024 | 6:58 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb's Checkmate-067 trial shows a significant long-term survival benefit with Opdivo + Yervoy in advanced melanoma, with over 40% of patients alive after ten years.
The trial results demonstrate a significant improvement in long-term survival rates for advanced melanoma patients treated with Opdivo + Yervoy. This positive outcome is likely to enhance the perception of Bristol Myers Squibb's oncology portfolio, potentially boosting investor confidence and positively impacting the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100